Pliant Therapeutics, Inc. (PLRX)

Pliant Therapeutics' stock (PLRX) has experienced a significant decline, decreasing by 89.01% over the last 12 months. Key events impacting the stock in the past six months include updates on BEACON-IPF, corporate updates and financial results, presentation of data from the Bexotegrast program, highlighting interim data from the INTEGRIS-PSC Phase 2a trial, reporting third-quarter 2025 financial results, announcing interim data from PLN-101095, and the discontinuation of the BEACON-IPF Phase 2b trial due to a safety-related imbalance.

Information regarding specific demand seasonality for Pliant Therapeutics, Inc.'s products and services is not explicitly detailed. Some financial platforms offer tools to identify seasonal patterns for PLRX, but access to this data typically requires a subscription or account.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for fibrosis and related diseases. The company operates in the biotechnology and pharmaceuticals industry, utilizing a platform to develop small molecule therapeutics that modulate key signaling pathways involved in fibrotic processes. Its major product candidates include Bexotegrast (PLN-74809) for IPF and PSC, PLN-1474 for NASH-related liver fibrosis, PLN-101095 for solid tumors resistant to immune checkpoint inhibitors, and PLN-101325 for muscular dystrophies.

Pliant Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company's broader operational or market geographic footprint beyond its headquarters is not explicitly detailed.

Pliant Therapeutics' brand reputation has been influenced by its clinical trial progress and financial performance. Analysts currently have a consensus "Hold" rating for the stock. The discontinuation of the BEACON-IPF Phase 2b trial has likely impacted the company's reputation, raising concerns about its pipeline. However, encouraging signs for bexotegrast in primary sclerosing cholangitis and positive interim data for PLN-101095 in solid tumors could positively influence its reputation.

Pliant Therapeutics, Inc. is primarily owned by institutional shareholders (82.03%) and company insiders (42.83%), with a smaller percentage held by retail investors (0.00%). Major institutional owners include Tang Capital Management LLC, Woodline Partners LP, and Point72 Asset Management, L.P. The largest individual shareholder is Matthew G. Robinson, who owns 16.07 million shares, representing 26.15% of the company.